extract: claynosaurz-new-entertainment-playbook

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -115,10 +115,16 @@ International generic competition beginning January 2026 (Canada patent expiry,
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
+*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
 
 If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
 
 Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon's 192,000+ patient analysis adds cancer risk reduction to the multi-organ benefit profile: female GLP-1 users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence. Also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for alcohol/drug abuse and bariatric surgery. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests benefits may be larger for women, which has implications for risk adjustment in Medicare Advantage.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -97,10 +97,16 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
+*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
 
 Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+
+Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging.
+
 ---
 
 Relevant Notes:

inbox/archive/general/claynosaurz-mediawan-animated-series.md

@@ -0,0 +1,51 @@
+---
+source_type: "article"
+title: "Mediawan Kids and Family to Turn Viral NFT Brand Claynosaurz Into Animated Series"
+author: "Elsa Keslassy (Variety)"
+url: "https://variety.com/2025/tv/news/mediawan-kids-family-nft-brand-claynosaurz-animated-series-1236411731/"
+date_published: "2025-06-02"
+date_archived: "2025-06-02"
+archived_by: "clay"
+domain: "entertainment"
+status: processed
+claims_extracted:
+  - "progressive validation through community building reduces development risk by proving audience demand before production investment"
+  - "traditional media buyers now seek content with pre-existing community engagement data as risk mitigation"
+---
+# Mediawan Kids & Family to Turn Viral NFT Brand Claynosaurz Into Animated Series (EXCLUSIVE)
+
+Source: Variety
+
+Originally published June 2nd, 2025
+
+Link: https://variety.com/2025/tv/news/mediawan-kids-family-nft-brand-claynosaurz-animated-series-1236411731/
+
+By Elsa Keslassy
+
+Mediawan Kids & Family, the youth content arm of the European powerhouse that owns Plan B, See-Saw Films and Chapter 2, has struck a deal with Claynosaurz Inc., the company behind the viral NFT brand. Together, they'll co-produce an animated series based on the digital-native franchise.
+
+The series, running 39 episodes of seven minutes each, underscores the strategy deployed by Mediawan Kids & Family to partner up with up-and-coming talent from the creator economy and develop original transmedia projects.
+
+Aimed at children aged 6 to 12, the comedy-filled series will follow the adventures of four dinosaur friends on a mysterious island. Jesse Cleverly, the award-winning co-founder and creative director of Mediawan-owned, Bristol-based banner Wildseed Studios, is on board as showrunner.
+
+Claynosaurz, created in 2021 by Nicholas Cabana, Dan Cabral and Daniel Jervis (former VFX artists at Sony Pictures, Animal Logic and Framestore) has already garnered over 450 million views and 200 million impressions across digital platforms, as well as an online community of over 530,000 subscribers with its humorous short videos. The brand has won 11 Collision Award, as well as a Webby Award.
+
+Julien Borde, Mediawan Kids & Family president, told Variety that the series will likely be the first of its kind and addresses a demand from buyers for content that “comes with a pre-existing engagement and data."
+
+#
+"I think it's the very first time a digital collectible brand is expanded into a TV series so it's a milestone, not just for Mediawan Kids & Family but for the industry,” Borde said. The project also allows the company to keep up with its mantra to “empower talents all around the world," the veteran youth content exec said, adding that the Claynosaurz team “are really into animation, have done fantastic shows in the past and are trying to do things a different way." Borde also said the show is part of Mediawan Kids & Family's ambition to diversify and build a new line-up of premium content coming from different platforms.
+
+Cabana said he created Claynosaurz with a “group of artists from all sorts of studios, including Illumination, Dreamworks, Sony, Disney and Ubisoft.” Having entered the market through collectibles and NFTs gave them the opportunity to monetize early in their development cycle and focus on building the characters rather than building long-form content, he said. The way they “flipped the traditional model” and “built the IP directly with fans" felt right because they could “prepackage the brand within the audience" at a time when it's "tough for large studios to take a risk on nascent brands if they're not proven or battle-tested," Cabana said.
+
+When Mediawan approached them, they “immediately understood the tone, warmth and irreverent humour that define Claynosaurz, and share our belief that great franchises can emerge from unexpected places,” Cabana said. He noted that “this type of community-driven development isn't just different, it's necessary.”
+
+The series will aim at getting the digital franchise to an even wider audience with “hyper relatable" content, while keeping the comedy-driven, quirky DNA of the hit IP, Cabana said. He also explained how the banner will test creative ideas on social media and “treat it as our test kitchen” to “find out what's sticking and what's not sticking,” he said.
+
+The show will launch on Youtube and will be available for licensing by traditional TV channels and platforms. Nicolas Fisch, who is producing the series for Mediawan Kids & Family, said Claynosaurz's creative teams and Mediawan's will come together in a writers room.
+
+#
+Katell France (“Vic the Vicking”) at Method Animation (“The Little Prince”), a Mediawan label, is producing the show with Cabana at Claynosaurz.
+
+Mediawan was at the Cannes Film Festival this year with the animated feature "Marcel et Monsieur Pagnol" directed by Sylvain Chomet (“The Triplets of Belleville").
+
+The image is a document containing an article titled "Mediawan Kids & Family to Turn Viral NFT Brand Claynosaurz Into Animated Series (EXCLUSIVE)". The article discusses Mediawan Kids & Family's deal with Claynosaurz Inc. to co-produce an animated series based on the digital-native franchise. The article includes quotes from Julien Borde, Mediawan Kids & Family president, and Nicholas Cabana, creator of Claynosaurz. The article also mentions that the show will launch on Youtube and will be available for licensing by traditional TV channels and platforms.

inbox/archive/health/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -7,13 +7,17 @@ date: 2026-01-13
 domain: health
 secondary_domains: [internet-finance]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
 processed_by: vida
 processed_date: 2026-03-18
 enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -64,3 +68,16 @@ flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health inves
 - Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
 - Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
 - Study released January 13, 2026
+
+
+## Key Facts
+- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
+- Study released January 13, 2026
+- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
+- After 12 months: medical costs grow 2% vs 6% for non-users
+- Diabetes indication at 30 months: medical cost growth 6 percentage points lower; 9 points lower with 80%+ adherence
+- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use
+- Female GLP-1 users: ~50% lower ovarian cancer incidence
+- Female GLP-1 users: 14% lower breast cancer incidence
+- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
+- Also associated with lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations

inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json

@@ -1,13 +1,13 @@
 {
   "rejected_claims": [
     {
-      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
+      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
       "issues": [
         "missing_attribution_extractor"
       ]
     },
     {
-      "filename": "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md",
+      "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -19,14 +19,14 @@
     "fixed": 2,
     "rejected": 2,
     "fixes_applied": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
-      "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:set_created:2026-03-18"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-19",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md:set_created:2026-03-19"
     ],
     "rejections": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
-      "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:missing_attribution_extractor"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-in-women-suggesting-multi-system-benefits-beyond-metabolic-endpoints.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",
-  "date": "2026-03-18"
+  "date": "2026-03-19"
 }

inbox/queue/.extraction-debug/claynosaurz-mediawan-animated-series.json

@@ -0,0 +1,25 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "community-validation-before-production-reduces-media-development-risk.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 1,
+    "fixes_applied": [
+      "community-validation-before-production-reduces-media-development-risk.md:set_created:2026-03-19",
+      "community-validation-before-production-reduces-media-development-risk.md:stripped_wiki_link:the-fanchise-engagement-ladder-from-content-to-co-ownership-"
+    ],
+    "rejections": [
+      "community-validation-before-production-reduces-media-development-risk.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-19"
+}

inbox/queue/claynosaurz-mediawan-animated-series.md

@@ -7,10 +7,14 @@ date_published: "2025-06-02"
 date_archived: "2025-06-02"
 archived_by: "clay"
 domain: "entertainment"
-status: unprocessed
+status: null-result
 claims_extracted:
   - "progressive validation through community building reduces development risk by proving audience demand before production investment"
   - "traditional media buyers now seek content with pre-existing community engagement data as risk mitigation"
+processed_by: leo
+processed_date: 2026-03-19
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "LLM returned 1 claims, 1 rejected by validator"
 ---
 # Mediawan Kids & Family to Turn Viral NFT Brand Claynosaurz Into Animated Series (EXCLUSIVE)
 
@@ -49,3 +53,15 @@ Katell France (“Vic the Vicking”) at Method Animation (“The Little Prince
 Mediawan was at the Cannes Film Festival this year with the animated feature "Marcel et Monsieur Pagnol" directed by Sylvain Chomet (“The Triplets of Belleville").
 
 The image is a document containing an article titled "Mediawan Kids & Family to Turn Viral NFT Brand Claynosaurz Into Animated Series (EXCLUSIVE)". The article discusses Mediawan Kids & Family's deal with Claynosaurz Inc. to co-produce an animated series based on the digital-native franchise. The article includes quotes from Julien Borde, Mediawan Kids & Family president, and Nicholas Cabana, creator of Claynosaurz. The article also mentions that the show will launch on Youtube and will be available for licensing by traditional TV channels and platforms.
+
+
+## Key Facts
+- Claynosaurz has generated 450M+ views and 200M+ impressions across digital platforms
+- Claynosaurz has 530K+ subscribers
+- Claynosaurz won 11 Collision Awards and 1 Webby Award
+- The Mediawan/Claynosaurz series will be 39 episodes of 7 minutes each
+- The series targets children aged 6-12
+- Jesse Cleverly from Wildseed Studios is showrunner
+- The series will launch on YouTube and be available for licensing to traditional TV channels
+- Katell France at Method Animation is producing with Nicholas Cabana
+- Mediawan presented 'Marcel et Monsieur Pagnol' at Cannes 2025